Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Hypertension. 2000;36:291-295

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, A.
Right arrow Articles by Keaney, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, A.
Right arrow Articles by Keaney, J. F., Jr
Related Collections
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Hypertension - basic studies

(Hypertension. 2000;36:291.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Ascorbic Acid and Glutathione Modulate the Biological Activity of S-Nitrosoglutathione

Aiming Xu; Joseph A. Vita; John F. Keaney, Jr

From the Evans Memorial Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass.

Correspondence to Dr John F. Keaney, Jr, Whitaker Cardiovascular Institute, Boston University School of Medicine, 80 E Concord St, Room W507, Boston, MA 02118. E-mail jkeaney{at}bu.edu


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Abstract—Ascorbic acid and glutathione (GSH) are important determinants of the intracellular redox state, and both are known to accelerate the decomposition of S-nitrosoglutathione (GSNO), an endogenous adduct of nitric oxide (NO). The implications of these observations for GSNO bioactivity are not yet clear. We investigated the effect of ascorbic acid and GSH on GSNO bioactivity by using a bioassay with isolated segments of guinea pig aorta suspended in organ chambers. Arterial segments demonstrated relaxation to GSNO (0.1 µmol/L) that was significantly enhanced by 300 µmol/L ascorbic acid (71±6% versus 53±6%, P<0.05) but not GSH. Both ascorbic acid and GSH significantly shortened the duration of arterial relaxation in response to 0.1 µmol/L GSNO (from >120 minutes to 22.5±3.5 and 36.3±4.3 minutes, respectively; P<0.05), consistent with accelerated decomposition of GSNO that was confirmed spectrophotometrically. The effect of ascorbic acid was abrogated by either DTPA or the copper(I)-specific agent bathocuproine but not deferoxamine, indicating a dependence on the availability of redox-active copper. Consistent with this notion, the action of ascorbic acid on GSNO bioactivity was also supported by copper-zinc superoxide dismutase, a physiologically relevant source of copper. In contrast, the effect of GSH on GSNO degradation and GSNO-mediated arterial relaxation was independent of transition metal ions, because DTPA had no effect. These data indicate that both ascorbic acid and GSH modulate GSNO bioactivity and suggest a distinction between the mechanism of GSNO degradation by ascorbic acid or GSH. Whereas both ascorbic acid and GSH accelerate the degradation of GSNO, only ascorbic acid is dependent on the presence of transition metal ions.


Key Words: antioxidants • oxidation-reduction • blood vessels • nitric oxide • S-nitrosoglutathione • relaxation


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Vascular homeostasis is dependent, in part, on nitric oxide (NO),1 a free radical that is synthesized enzymatically from L-arginine and O2 by an endothelial isoform of nitric oxide synthase.1 NO contributes to resting vascular tone,2 impairs platelet activation,3 prevents leukocyte adhesion to the endothelium,4 and inhibits vascular smooth muscle migration5 and proliferation.6 Mice lacking endothelial nitric oxide synthase are hypertensive,7 8 and impaired NO bioactivity in diabetes and atherosclerosis is thought to contribute to vascular disease (reviewed in Reference 9 ). Thus, NO is an important mediator of vascular homeostasis.

Under aerobic conditions, NO can combine with O210 or reduced thiols11 to form S-nitrosothiols, which possess bioactivity similar to authentic NO.12 13 In the intracellular space, the abundance of glutathione (GSH; 1 to 5 mmol/L14 ) renders the formation of S-nitrosoglutathione (GSNO) kinetically feasible,11 15 16 and GSNO formation has been implicated in cellular functions such as neutrophil oxidant production17 and signal transduction.18 The precise metabolic fate of GSNO and its implications for NO bioactivity, however, remain unclear.

Recent evidence suggests that S-nitrosothiol metabolism is sensitive to the local reducing environment. Reduced transition metal ions such as Cu+ catalyze the decomposition of S-nitrosothiols more effectively than do their oxidized forms (eg, Cu2+).16 19 20 Both ascorbic acid21 and GSH22 accelerate the decomposition of GSNO in vitro and may modulate the release of NO from S-nitrosothiols.23 Enhanced release of NO from S-nitrosothiols has been shown to augment the hypotensive response to these agents.24 However, the effect of ascorbic acid and GSH on the NO-like bioactivity of GSNO is not clear and serves as the purpose of the present study.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Materials
Sodium nitrite was purchased from Fisher Scientific. Sulfanilamide and N-(1-naphthyl)ethylenediamine dihydrochloride were obtained from Aldrich Chemical Co. Chelex-100 resin was purchased from Bio-Rad Laboratories, whereas DTPA, GSH, prostaglandin F2{alpha} (PGF2{alpha}), and all other compounds were purchased from Sigma Chemical Co.

Physiological salt solution (PSS) contained 118.3 mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 25 mmol/L NaHCO3, and 11.1 mmol/L glucose. All solutions were prepared with double-distilled water and treated with Chelex before use. All glassware was acid-washed followed by thorough flushing with Chelex-treated water. Solutions of NO and GSNO were synthesized and quantified immediately before use as described.12 25 26

NO Bioassay
The NO-like bioactivity of GSNO was assessed in a PSS buffer system with vascular relaxation as a bioassay with segments of Hartley guinea pig thoracic aorta. Animals (450 to 500 g) were killed with CO2, and aortic ring segments (5 mm) without endothelium were prepared and suspended in organ chambers as described.27 Organ chambers were acid-washed followed by copious flushing with Chelex-treated water to minimize contamination with metal ions. With this treatment, the buffer metal ion content (as assessed by ascorbate oxidation28 ) was reduced from 6±2 to <0.01 µmol/L (n=3). Animal studies were approved by the Boston University Medical Campus Institutional Animal Care and Use Committee.

Quantification of GSNO Degradation
Time-dependent changes in GSNO concentration were monitored continuously at 332 nm ({epsilon}=750 mol/L-1 · cm-1) over a period of 100 minutes with the use of a Varian Cary 3 dual-beam spectrophotometer at 37°C. The rate of GSNO decay as a function of time (d[GSNO]/dt) was determined by the initial slope of the decay curve over the first 10 minutes of incubation.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Effect of Ascorbic Acid and GSH on GSNO-Induced Arterial Relaxation
We used arterial relaxation as a marker for the NO-like bioactivity of GSNO. Extracellular GSNO added to organ chambers produced dose-dependent arterial relaxation that was mildly enhanced by physiologically relevant ascorbic acid (>0.1 mmol/L) in the buffer (Figure 1A; P<0.05 for ascorbate versus control by 2-way ANOVA). Higher concentrations of ascorbic acid produced no additional effect. In contrast, GSNO-mediated arterial relaxation was not materially altered by GSH (Figure 1B), and no vasodilation was observed with decomposed GSNO (data not shown). Thus, ascorbic acid but not GSH modestly augments the extent of GSNO-induced arterial relaxation.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1. Ascorbic acid but not GSH enhances GSNO-mediated arterial relaxation. Segments of thoracic aorta were harvested from Hartley guinea pigs as described in Methods. Vessels were contracted with PGF2{alpha}, and relaxation was assayed in response to the indicated concentrations of GSNO in the presence of PSS containing no additions ({square}) or either ascorbic acid (A) or GSH (B) at concentrations of 0.1 ({triangleup}), 0.3 ({lozenge}), or 1 ({circ}) mmol/L. Data are derived from 5 to 7 experiments. *P<0.05 vs PSS alone by 2-way ANOVA.

Ascorbic acid and GSH had more uniform effects on the duration of GSNO-mediated arterial relaxation. Contracted arterial segments exposed to GSNO (0.1 µmol/L) demonstrated stable relaxation that was shortened considerably by 300 µmol/L ascorbic acid or GSNO (Figure 2A). Quantitatively, the half-time of GSNO (0.1 µmol/L) arterial relaxation (ie, the time required to restore 50% of the tension reduction produced by a vasodilator) exceeded 120 minutes (Figure 2B) and decreased to 22.5±3.5 minutes and 36.3±4.3 minutes in the presence of ascorbic acid and GSH, respectively (both P<0.05 versus control by 1-way ANOVA; n=6). Thus, both ascorbic acid and GSH appear to accelerate GSNO decomposition manifested as a shorter duration of arterial relaxation.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Ascorbic acid (AA) and the duration of GSNO-mediated arterial relaxation. Segments of thoracic aorta were harvested from Hartley guinea pigs as described in Methods. A, Vessels were contracted with PGF2{alpha}, and the duration of relaxation was assayed in response to 0.1 µmol/L GSNO in the presence or absence of 0.3 mmol/L ascorbic acid or GSH. B, Composite data on the duration of GSNO-mediated arterial relaxation derived from the half-time of arterial relaxation as described in Methods. Data are mean±SEM of 6 experiments. CTL indicates control. *P<0.05 vs no additions.

Transition Metal Ions and Ascorbic Acid–Induced GSNO Decomposition
The decomposition of GSNO has been linked to reduced transition metal ions,29 and ascorbic acid is known to reduce the valence state of transition metal ions in solution.30 In the presence of DTPA, a strong metal chelator, we found that ascorbic acid had no effect on the duration of GSNO-mediated arterial relaxation (Figure 3). Specific chelation of Cu(I) with 100 µmol/L bathocuproine sulfonate31 also abrogated the effect of ascorbic acid, whereas the iron-specific chelator deferoxamine (100 µmol/L) was ineffective (Figure 3).



View larger version (21K):
[in this window]
[in a new window]
  		Figure 3. Transition metal ions and ascorbic acid– (AA-) induced GSNO decomposition. Segments of thoracic aorta were harvested from Hartley guinea pigs as described in Methods. A, Original tracings of vessels contracted with PGF2{alpha} and exposed to 0.1 µmol/L GSNO in the presence or absence of 0.3 mmol/L ascorbic acid with or without DTPA (100 µmol/L), bathocuproine (BC; 100 µmol/L), or deferoxamine (DFO; 100 µmol/L). B, Composite data on the duration of GSNO-mediated arterial relaxation derived from the half-time of arterial relaxation as described in Methods. Data are mean±SEM of 6 experiments. CTL indicates control. *P<0.05 vs no additions.

To examine the kinetics of GSNO decomposition, we followed GSNO decay as the change in absorbance at 332 nm. As shown in Figure 4, GSNO decay was significantly enhanced by ascorbic acid, and this effect was inhibited by chelation of transition metals with DTPA (Figure 4). The effect of ascorbic acid was specific for Cu(I), because it was inhibited by bathocuproine and not affected by deferoxamine (Figure 4). Individually, copper and ascorbic acid enhanced GSNO degradation, and their combination was additive (Figure 4). Thus, ascorbic acid enhances GSNO decomposition in a copper-dependent manner.



View larger version (14K):
[in this window]
[in a new window]
  		Figure 4. Ascorbic acid and GSNO decomposition. GSNO (500 µmol/L) was incubated in Chelex-treated PSS with or without the indicated concentrations of ascorbic acid (AA), DTPA, bathocuproine (BC), deferoxamine (DFO), or CuSO4 (Cu). Decomposition of GSNO (d[GSNO]/dt) was monitored spectrophotometrically at 332 nm ({epsilon}=750 mol/L-1 · cm-1) at 37°C. Data are mean±SEM from 3 independent experiments. *P<0.05 vs no additions; {dagger}P<0.05 vs AA alone.

Transition Metal Ions and GSH-Induced GSNO Decomposition
Arterial relaxation to GSNO (0.1 µmol/L) was significantly shortened by GSH (Figures 5A and 5B), but this effect was only partially inhibited by DTPA (Figure 5A) and not materially altered in the presence of copper or deferoxamine (Figure 5B). Consistent with this observation, GSNO decay was significantly enhanced by GSH (Figure 6). However, the effect of GSH on GSNO decay was not significantly inhibited by chelation of transition metals with DTPA (Figure 6). In fact, GSH actually inhibited the action of copper to enhance GSNO decomposition (Figure 6). Thus, GSH accelerates GSNO decay through a mechanism that appears largely independent of transition metals.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 5. Transition metal ions and GSH-induced GSNO decomposition. Segments of thoracic aorta were harvested from Hartley guinea pigs as described in Methods. A, Original tracings of vessels contracted with PGF2{alpha} and exposed to 0.1 µmol/L GSNO in the presence or absence of 0.3 mmol/L GSH with or without DTPA (100 µmol/L). B, Composite data on the duration of GSNO-mediated arterial relaxation derived from the half-time of arterial relaxation as described in Methods. Data are mean±SEM of 6 experiments. CTL indicates control; DFO, deferoxamine. *P<0.05 vs no additions.



View larger version (14K):
[in this window]
[in a new window]
  		Figure 6. GSH and GSNO decomposition. GSNO (500 µmol/L) was incubated in Chelex-treated PSS with or without the indicated concentrations of GSH, DTPA, or CuSO4 (Cu). Decomposition of GSNO (d[GSNO]/dt) was monitored spectrophotometrically at 332 nm ({epsilon}=750 mol/L-1 · cm-1) at 25°C. Data are mean±SEM from 3 independent experiments. *P<0.05 vs no additions; {dagger}P<0.05 vs Cu alone.

The availability of redox-active copper in vivo is controversial.32 We sought to determine whether a physiologically relevant source of copper (eg, copper-zinc superoxide dismutase [Cu-Zn SOD]) would support the effects of ascorbic acid on GSNO-mediated arterial relaxation. As shown in Figure 7, Cu-Zn SOD enhanced the effect of ascorbic acid on GSNO-mediated arterial relaxation, and this effect was inhibited by DTPA. In contrast, Cu-Zn SOD had no effect on the ability of GSH to shorten the duration of GSNO-mediated arterial relaxation (Figure 7).



View larger version (21K):
[in this window]
[in a new window]
  		Figure 7. Cu-Zn SOD and GSNO-mediated arterial relaxation. Segments of thoracic aorta were harvested from Hartley guinea pigs as described in Methods, contracted with PGF2{alpha}, and exposed to 0.1 µmol/L GSNO in the presence or absence of 0.3 mmol/L ascorbic acid (AA) (A) or GSH (B) with or without the indicated concentrations of Cu-Zn SOD or 100 µmol/L DTPA. Data are mean±SEM of 6 experiments. *P<0.05 vs no additions; effect of Cu-Zn SOD was significant by 1-way ANOVA (P<0.01).


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
The data presented here indicate that both ascorbic acid and GSH modulate the bioactivity of S-nitrosoglutathione measured as arterial relaxation. Specifically, ascorbic acid increased the extent of GSNO-mediated arterial relaxation. Both ascorbic acid and GSH appeared to accelerate the decomposition of GSNO because the duration of GSNO-mediated arterial relaxation was reduced by both compounds. The effect of ascorbic acid and GSH on GSNO decomposition was confirmed by spectrophotometric studies that followed the kinetics of GSNO degradation. Ascorbic acid and GSH appeared to modulate the bioactivity of GSNO through distinct mechanisms. We found that the ability of ascorbic acid to accelerate GSNO decomposition was copper dependent. In contrast, GSH accelerated GSNO decomposition without enhancing its bioactivity, and this effect was not dependent on copper. These data suggest that ascorbic acid and GSH may modulate GSNO action and metabolism.

The role of ascorbic acid in GSNO metabolism has been examined previously. Kashiba-Iwatsuki and colleagues21 found by electron spin resonance that extracellular levels of ascorbic acid (50 to 100 µmol/L) stimulated the decomposition of GSNO in vitro in association with ascorbyl radical production and that 2 moles of GSNO were consumed per mole of ascorbic acid. The data presented here extend these observations by linking the enhanced degradation of GSNO to an increased NO flux enhancing the extent (Figure 1) of GSNO-mediated arterial relaxation and reducing its duration of action (Figure 2). In contrast to prior studies,21 33 we found that the effect of ascorbic acid on GSNO-mediated arterial relaxation was dependent on the presence of copper (Figures 3 and 4). One possible explanation for this discrepancy might relate to tissue sources of metal ions or our bicarbonate buffer system compared with the phosphate system of Kashiba-Iwatsuki and colleagues.

Catalytic quantities of both copper and iron20 are known to accelerate the decomposition of S-nitrosothiols. Specifically, the reduced forms (eg, Cu+ and Fe2+) of these metal ions are responsible for the catalysis of S-nitrosothiol decomposition.16 19 20 Because both ascorbic acid and GSH reduce copper and iron,30 it is reasonable to speculate that both agents enhance GSNO bioactivity through transition metal reduction. Although our data support such speculation for ascorbic acid, the effect of GSH on GSNO decomposition and its NO-like bioactivity was not materially altered by metal ion chelation with DTPA (Figure 5). This observation is readily explained by observations that GSH forms a redox-inactive complex with copper34 35 36 at molar ratios of GSH:Cu exceeding 2.19 37 Given that our experiments were performed with a GSH concentration of 300 µmol/L (Figures 5 and 6) and that the contaminating metal ion concentration was <0.01 µmol/L, our conditions favored GSH-Cu(I) complex formation,37 thus explaining the lack of copper dependence. Although Fe(II) supports the decomposition of GSNO,19 20 it is unlikely that GSH-mediated GSNO decomposition involved iron, because DTPA and deferoxamine had no effect on this process (Figure 6).

There are data to suggest that GSH-mediated GSNO decomposition proceeds in the absence of transition metal ions. Hogg and coworkers23 used a metal ion–free system and found that GSNO formed in the presence of excess GSH was unstable, suggesting a direct reaction between GSH and GSNO. The proposed product of this reaction was peroxynitrite, a compound with limited vasodilating bioactivity compared with authentic NO.38 39 With this scenario, one would predict that GSH-mediated GSNO decomposition would not lead to enhanced NO-like bioactivity, consistent with the results reported here (Figure 1B). Thus, metal ion–independent reaction of GSH with GSNO can account for the reduced GSNO-mediated arterial relaxation in the presence of millimolar concentrations of GSH.

One important issue to consider is the relevance of our findings for S-nitrosothiol action and metabolism in vivo. Considerable evidence indicates that S-nitrosothiols are formed in vivo, and protein S-nitrosylation has been implicated in the modulation of energy metabolism,17 signal transduction,40 apoptosis,41 and even blood flow.42 For such events to be reversible, the cellular environment must provide some mechanism(s) to restore nitrosothiols back to their reduced form. Singh and colleagues16 have proposed that GSNO serves as a sink for functional protein NO+ moieties, leading to the "repair" of S-nitrosylated proteins, and that GSH-mediated GSNO decomposition facilitates this repair mechanism. Our data and those of others19 39 indicate that ascorbic acid may also facilitate GSNO decomposition, perhaps through copper-containing enzymes such as SOD (Figure 7),43 and enhance the NO-like bioactivity of GSNO (Figure 1). Prior reports that ascorbic acid enhances NO bioactivity44 and reduces blood pressure45 have prompted speculation on the role of GSNO decomposition in these observations.

In summary, the data presented here indicate that both ascorbic acid and GSH enhance the decomposition of GSNO. In the case of ascorbic acid, accelerated GSNO decomposition is metal ion dependent and associated with a modest increase in bioactivity (eg, vasodilation) that is reduced in duration. With GSH, however, accelerated GSNO decomposition is not metal ion dependent and does not seem to result in enhanced bioactivity. Instead, the main effect is a reduction in the duration of GSNO bioactivity. These data suggest that the reducing environment within the cell has important implications for S-nitrosothiol bioactivity.


*    Acknowledgments
 
This work was supported by grants from the National Institutes of Health (HL-53398 to J.A.V. and HL-59346 to J.F.K.). Joseph A. Vita is an Established Investigator of the American Heart Association, and John F. Keaney, Jr, is the recipient of a Clinical Investigator Development Award (HL-03195) from the National Institutes of Health.

Received October 20, 1999; first decision November 12, 1999; accepted February 25, 2000.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A. 1992;89:6348–6352.[Abstract/Free Full Text]
  2. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation. J Clin Invest. 1995;95:1747–1755.
  3. Welch GN, Upchurch GR Jr, Loscalzo J. Nitric oxide as a vascular modulator. Blood Rev. 1996;9:262–269.
  4. Kubes P, Kurose I, Granger DN. NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules. Am J Physiol. 1994;267:H931–H937.[Abstract/Free Full Text]
  5. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 1995;95:2630–2638.
  6. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cGMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777.
  7. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239–242.[Medline] [Order article via Infotrieve]
  8. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996;93:13176–13181.[Abstract/Free Full Text]
  9. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis. 1995;38:129–154.[Medline] [Order article via Infotrieve]
  10. Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval F, Laval J, Cook JA, Krishna MC. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH: insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol. 1994;7:519–525.[Medline] [Order article via Infotrieve]
  11. Gow AJ, Buerk DG, Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J Biol Chem. 1997;272:2841–2845.[Abstract/Free Full Text]
  12. Keaney JF Jr, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, Loscalzo J. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest. 1993;91:1582–1589.
  13. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992;258:1898–1902.[Abstract/Free Full Text]
  14. Bray TM, Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol. 1993;71:746–751.[Medline] [Order article via Infotrieve]
  15. Kharitonov VG, Sundquist AR, Sharma VS. Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. J Biol Chem. 1995;270:28158–28164.[Abstract/Free Full Text]
  16. Singh RJ, Hogg N, Joseph J, Kalyanaraman B. Mechanism of nitric oxide release from S-nitrosothiols. J Biol Chem. 1996;271:18596–18603.[Abstract/Free Full Text]
  17. Clancy RM, Levartovsky D, Leszczynska-Piziak J, Yegudin J, Abramson SB. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci U S A. 1994;91:3680–3684.[Abstract/Free Full Text]
  18. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, Kraemer RT, Mirza UA, Chait BR, Burk SC, Quilliam LA. Redox regulation of cell signalling. Nature. 1996;381:380–381.[Medline] [Order article via Infotrieve]
  19. Gorren ACF, Schrammel S, Schmidt K, Mayer B. Decomposition of S-nitrosoglutathione in the presence of copper ions and glutathione. Arch Biochem Biophys. 1996;330:219–228.[Medline] [Order article via Infotrieve]
  20. Williams DLH. S-nitrosothiols and role of metal ions in decomposition to nitric oxide. Methods Enzymol. 1996;268:299–308.[Medline] [Order article via Infotrieve]
  21. Kashiba-Iwatsuki M, Yamaguchi M, Inoue M. Role of ascorbic acid in the metabolism of S-nitroso-glutathione. FEBS Lett. 1996;389:149–152.[Medline] [Order article via Infotrieve]
  22. Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, Feelisch M. No NO from NO synthase. Proc Natl Acad Sci U S A. 1996;93:14492–14497.[Abstract/Free Full Text]
  23. Hogg N, Singh RJ, Kalyanaraman B. The role of glutathione in the transport and catabolism of nitric oxide. FEBS Lett. 1996;382:223–228.[Medline] [Order article via Infotrieve]
  24. Scharfstein JS, Keaney JF Jr, Slivka A, Welch GN, Vita JA, Stamler JS, Loscalzo J. In vivo transfer of NO between a plasma protein-bound reservoir and low-molecular-weight thiols. J Clin Invest. 1994;94:1432–1439.
  25. Saville B. A scheme for the determination of microgram amounts of thiols. Analyst. 1958;83:670–672.
  26. Lynch SM, Frei B, Morrow JD, Roberts LJ II, Xu A, Jackson T, Reyna R, Klevay LM, Vita JA, Keaney JF Jr. Vascular superoxide dismutase deficiency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation. Arterioscler Thromb Vasc Biol. 1997;17:2975–2981.[Abstract/Free Full Text]
  27. Jackson TS, Lerner E, Weisbrod RM, Tajima M, Loscalzo J, Keaney JF Jr. The vasodilatory properties of recombinant maxadilan. Am J Physiol. 1996;271:H924–H930.[Abstract/Free Full Text]
  28. Buettner GR. Ascorbate oxidation: UV absorbance of ascorbate and ESR spectroscopy of the ascorbyl radical as assays for iron. Free Radic Res Commun. 1990;10:5–9.[Medline] [Order article via Infotrieve]
  29. McAninly J, Williams DLH, Askew SC, Butler AR, Russel C. Metal ion catalysis in nitrosothiol (RSNO) decomposition. J Chem Soc Chem Commun. 1993;93:1758–1759.
  30. Retsky K, Frei B. Vitamin C prevents metal ion-dependent initiation and propagation of lipid peroxidation in human low-density lipoprotein. Biochim Biophys Acta. 1995;1257:279–287.[Medline] [Order article via Infotrieve]
  31. Lynch SM, Frei B. Reduction of copper, but not iron, by human low density lipoprotein (LDL): implications for metal ion-dependent oxidative modification of LDL. J Biol Chem. 1995;270:5158–5163.[Abstract/Free Full Text]
  32. Stocker R, Frei B. Endogenous antioxidant defences in human blood plasma. In: Sies H, ed. Oxidative Stress: Oxidants and Antioxidants. London, England: Academic Press; 1991:213–243.
  33. Kashiba-Iwatsuki M, Kitoh K, Kasahara E, Yu H, Nisikawa M, Matsuo M, Inoue M. Ascorbic acid and reducing agents regulate the fates and functions of S-nitrosothiols. J Biochem (Tokyo). 1997;122:1208–1214.[Abstract/Free Full Text]
  34. Freedman JH, Ciriolo MR, Peisach J. The role of glutathione in copper metabolism and toxicity. J Biol Chem. 1989;264:5598–5605.[Abstract/Free Full Text]
  35. Milne L, Nicotera P, Orrenius S, Burkitt MJ. Effects of glutathione and chelating agents on copper-mediated DNA oxidation: pro-oxidant and antioxidant properties of glutathione. Arch Biochem Biophys. 1993;304:102–109.[Medline] [Order article via Infotrieve]
  36. Hanna PM, Mason RP. Direct evidence for inhibition of free radical formation from Cu(I) and hydrogen peroxide by glutathione and other potential ligands using the EPR spin-trapping technique. Arch Biochem Biophys. 1992;295:205–213.[Medline] [Order article via Infotrieve]
  37. Spear N, Aust SD. Hydroxylation of deoxyguanosine in DNA by copper and thiols. Arch Biochem Biophys. 1994;317:142–148.
  38. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, Tarpey MM. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:1044–1048.[Abstract/Free Full Text]
  39. Mayer B, Schrammel A, Klatt P, Koesling D, Schmidt K. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase: dependence on glutathione and possible role of S-nitrosation. J Biol Chem. 1995;270:17355–17360.[Abstract/Free Full Text]
  40. Gopalakrishna R, Chen ZH, Gundimeda U. Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem. 1993;268:27180–27185.[Abstract/Free Full Text]
  41. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS. Fas-induced caspase denitrosylation. Science. 1999;284:651–654.[Abstract/Free Full Text]
  42. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonoventura J, Gernert K, Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034–2037.[Abstract/Free Full Text]
  43. Jourd’heuil D, Laroux FS, Miles AM, Wink DA, Grisham MB. Effect of superoxide dismutase on the stability of S-nitrosothiols. Arch Biochem Biophys. 1999;361:323–330.[Medline] [Order article via Infotrieve]
  44. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 1996;96:1107–1113.
  45. Duffy S, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, Vita JA. Treatment of hypertension with ascorbic acid. Lancet. 1999;354:2048–2049.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 HypertensionHome page
S. Ulker, P. P. McKeown, and U. Bayraktutan
Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities
Hypertension, March 1, 2003; 41(3): 534 - 539.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D C Chambers and J G Ayres
Effects of nitrogen dioxide exposure and ascorbic acid supplementation on exhaled nitric oxide in healthy human subjects
Thorax, October 1, 2001; 56(10): 774 - 778.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
X. Chen, R. M. Touyz, J. B. Park, and E. L. Schiffrin
Antioxidant Effects of Vitamins C and E Are Associated With Altered Activation of Vascular NADPH Oxidase and Superoxide Dismutase in Stroke-Prone SHR
Hypertension, September 1, 2001; 38(3): 606 - 611.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, A.
Right arrow Articles by Keaney, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, A.
Right arrow Articles by Keaney, J. F., Jr
Related Collections
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Hypertension - basic studies

Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.